Design Therapeutics
DSGN
74 hedge funds and large institutions have $542M invested in Design Therapeutics in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 16 reducing their positions, and 7 closing their positions.
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
63% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 16
17% more funds holding
Funds holding: 63 → 74 (+11)
1.16% more ownership
Funds ownership: 68.21% → 69.36% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
12% less capital invested
Capital invested by funds: $614M → $542M (-$72.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.26M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.63M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.55M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$2.83M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.02M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$3.23M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.98M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.6M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$808K |
DSGN Hedge Fund Activity: Q2 2022 in Review
74 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2022, worth a combined $542M — down 12% from $614M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DSGN positions and 7 closed out — a net gain of 12 holders — while 26 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $5.26M. The largest seller was Vanguard Group, cutting an estimated $8.02M.
- 74 institutional investors held Design Therapeutics (DSGN) as of Q2 2022, up from 63 in Q1 2022.
- Funds reported $542M of Design Therapeutics stock for Q2 2022, down 12% quarter-over-quarter.
- 19 funds opened new Design Therapeutics positions in Q2 2022 and 7 closed out, a net change of +12 holders.
- The largest Design Therapeutics buyer in Q2 2022 was BlackRock, an estimated $5.26M added.
- The largest Design Therapeutics seller in Q2 2022 was Vanguard Group, an estimated $8.02M sold.
Based on aggregated 13F filings for Q2 2022.